Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
BioXcel Therapeutics, Inc. (BTAI) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer",
"Astria Therapeutics October 2023 1 Exhibit 99.2 Cautionary Note Regarding Forward Looking Statements and Disclaimer This"
10/04/2023 8-K Regulation FD Disclosure  Interactive Data
08/22/2023 8-K Other Events  Interactive Data
08/14/2023 8-K Quarterly results
Docs: "BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic Reprioritization"
06/30/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/29/2023 8-K Other Events  Interactive Data
05/08/2023 8-K Quarterly results
Docs: "BioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational Highlights"
04/20/2023 8-K Quarterly results
03/16/2023 8-K Other Events  Interactive Data
03/15/2023 8-K Other Events  Interactive Data
03/09/2023 8-K Quarterly results
Docs: "BioXcel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights"
02/21/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended . Forward-looking statements in this presentation include but are not limited to: statements regarding BioXcel Therapeutics’ expected timing of, and data results from, trials and clinical studies involving its product candidates, in particular BXCL701; planned discussions with regulators and potential registrational trials; strategic options for OnkosXcel; and potential market size and opportunity for product cand..."
02/13/2023 8-K Quarterly results
11/30/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
09/12/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "® BioXcel Therapeutics | 555 Long Wharf Drive, 12th Floor | New Haven, CT 06511 | www.bioxceltherapeutics.com September 2022 AI-Driven Drug Development in Neuroscience and Immuno-oncology NASDAQ: BTAI"
08/19/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
07/21/2022 8-K Quarterly results
07/06/2022 8-K Quarterly results
07/05/2022 8-K Quarterly results
05/23/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/09/2022 8-K Quarterly results
Docs: "BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights"
04/19/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Company WARRANT NEITHER THIS WARRANT NOR THE SECURITIES ISSUABLE UPON ITS EXERCISE OR CONVERSION HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED , OR ANY APPLICABLE STATE SECURITIES LAW AND MAY NOT BE TRANSFERRED EXCEPT IN ACCORDANCE WITH THE SECURITIES ACT OR SUCH APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM, OR WHERE, IN THE OPINION OF COUNSEL, REGISTRATION UNDER THE SECURITIES ACTS OR SUCH APPLICABLE STATE SECURITIES LAWS IS NOT REQUIRED IN CONNECTION WITH SUCH PROPOSED TRANSFER.",
"Registration Rights Agreement is made as of April 19, 2022, by and among BioXcel Therapeutics, Inc., a Delaware corporation , the purchasers identified on Schedule A hereto (each, a “Purchaser"
04/07/2022 8-K Entry into a Material Definitive Agreement, Other Events  Interactive Data
03/10/2022 8-K Quarterly results
01/13/2022 8-K Results of Operations and Financial Condition, Regulation FD Disclosure  Interactive Data
12/01/2021 8-K Other Events  Interactive Data
11/10/2021 8-K Quarterly results
Docs: "BioXcel Therapeutics Reports Third Quarter 2021 Financial Results and Recent Operational Highlights"
10/25/2021 8-K Regulation FD Disclosure  Interactive Data
10/13/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/09/2021 8-K Quarterly results
08/10/2021 8-K Quarterly results
Docs: "BioXcel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Operational Highlights"
07/23/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy